Invesco Ltd. Cel Sci Corp Transaction History

Invesco Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $40,013 - $77,389	-15,509 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $1,469 - $2,879	-374 Reduced 2.35%	15,509 $61,000
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $2,683 - $4,845	-378 Reduced 2.32%	15,883 $113,000
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $23,439 - $38,319	3,068 Added 23.25%	16,261 $179,000
Q2 2021 Aug 17, 2021	BUY	$8.68 - $27.49 $6,839 - $21,662	788 Added 6.35%	13,193 $114,000
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $148,860 - $342,874	12,405 New	12,405 $188,000
Q2 2020 Aug 14, 2020	SELL	$9.75 - $17.6 $1.02 Million - $1.84 Million	-104,509 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$7.54 - $17.05 $111,343 - $251,777	-14,767 Reduced 12.38%	104,509 $1.21 Million
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $1.17 Million - $1.66 Million	-173,965 Reduced 59.32%	119,276 $1.09 Million
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $1.76 Million - $2.82 Million	293,241 New	293,241 $2.62 Million

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $46M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.